A 'Vote No' campaign with 13% ownership and public pressure may force board change; watch for ISS/Glass Lewis recommendations and pre-meeting proxy vote tallies. The June 11 annual meeting outcome is the key catalyst—a high 'Against' vote for Ms. James could drive governance reform and a stock re-rating.
Price Chart
Executive Summary
BBRC International, an activist holder of ~13% of VSCO shares, is escalating its 'Vote No' campaign against Chair Donna James ahead of the June 11 annual meeting, citing her 25-year tenure marked by poor oversight, failed M&A ($591M Adore Me), and $625M in misallocated buybacks. The campaign follows the recent withdrawal of director Mariam Naficy and management's adoption of a poison pill, signaling a contentious proxy fight.
Key Financial Metrics
Key Facts
- BBRC owns approximately 13% of VSCO shares (10,310,631 shares) and is running a 'Vote No' campaign against Chair Donna James.
- BBRC cites Ms. James's 25-year tenure, including $625M in poorly executed buybacks, the failed $591M Adore Me acquisition, and her role as defendant in the $90M Rudi v. Wexner lawsuit over Jeffrey Epstein oversight.
- Director Mariam Naficy withdrew her re-election on May 10, 2026, and the board size will reduce from 10 to 9 after the annual meeting.
- Annual meeting is scheduled for June 11, 2026; BBRC is not offering its own director slate but focusing solely on opposing Ms. James's re-election.
- Management adopted a shareholder rights plan (poison pill) on May 10, 2026, in response to BBRC's campaign.
Financial Impact
BBRC's campaign aims to replace the chair, potentially altering governance and capital allocation strategy; no immediate financial impact quantified.
Risk Factors
- Management's poison pill and board entrenchment could limit activist influence.
- If Ms. James is re-elected, BBRC may escalate with a full director slate or legal action.
- The proxy fight diverts attention from operational turnaround; continued stock underperformance possible.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DFAN14A Filing (Primary) | 0001213900-26-055778 |
| Document: 0001213900-26-055778-index-headers.html | 0001213900-26-055778 |
| Document: 0001213900-26-055778-index.html | 0001213900-26-055778 |
| Document: 0001213900-26-055778.txt | 0001213900-26-055778 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | — | awaiting T+20 | — | — |
Jun 4, 2026 20w ago | DEFA14A | $72.28 | awaiting T+20 | — | — |
Jun 3, 2026 20w ago | DEFA14A | $78.96 $76.71 | ▼ −2.85% | ▼ −1.85% | — |
Jun 2, 2026 20w ago | 8-K | $80.06 $88.50 | ▲ +10.54% | ▲ +12.11% | — |
Jun 2, 2026 20w ago | Press Release | $80.06 $88.50 | ▲ +10.54% | ▲ +12.11% | — |
May 21, 2026 22w ago | 8-K | $50.55 $81.98 | ▲ +62.18% | ▲ +61.84% | — |
May 20, 2026 22w ago | Press Release | $50.55 $81.98 | ▲ +62.18% | ▲ +61.84% | — |
May 18, 2026 23w ago | DEFA14A | $45.20 $78.88 | ▲ +74.51% | ▲ +73.53% | — |
May 18, 2026 23w ago | Press Release | $44.83 $78.88 | ▲ +75.95% | ▲ +74.37% | — |
May 13, 2026 23w ago | DFAN14A | $46.78 $78.88 | ▲ +68.62% | ▲ +69.48% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers